在马萨诸塞州无家可归者收容所提供丁丙诺啡的健康与经济结局
该经济评估研究使用马萨诸塞州的队列状态转换模拟模型,从2013年起模拟两个队列:一个由有高风险阿片类药物使用史的无家可归者(PEH)组成的封闭队列,另一个是成员可随时间变化的开放队列,以评估10年期间的人口水平趋势。模型比较了不提供收容所丁丙诺啡(现状)与全州收容所提供丁丙诺啡两种策略。在13 800名PEH的封闭队列分析中,收容所丁丙诺啡与个体终生额外65.4人周服用丁丙诺啡相关,从卫生部门角度每人贴现终生费用节省1300美元,每人额外获得0.2个贴现QALY和0.9个额外生命年。在人口水平模拟中,10年期间避免254例过量死亡(马萨诸塞州PEH中过量死亡减少9.2%)。作者认为,广泛推广收容所丁丙诺啡可能是应对过量危机的重要工具。
要点
- 在13 800名PEH的封闭队列中,收容所丁丙诺啡与个体终生额外65.4人周服用丁丙诺啡相关,从卫生部门角度每人贴现终生费用节省1300美元。
- 封闭队列中,收容所丁丙诺啡每人额外获得0.2个贴现QALY和0.9个额外生命年。
- 人口水平模拟中,10年期间收容所丁丙诺啡策略避免254例过量死亡,相当于马萨诸塞州PEH中过量死亡减少9.2%。
- 与过量相关的未贴现费用减少300万美元,其他医疗保健利用未贴现费用减少6640万美元。
- 收容所阿片类药物治疗产生额外药物和临床费用4470万美元,但节省了6940万美元的过量和其他健康费用。
适用人群与场景
- 马萨诸塞州有高风险阿片类药物使用史的无家可归者(PEH),包括封闭队列(固定人群终生模拟)和开放队列(成员可随时间变化,评估10年人口水平趋势)。
处置流程与药物剂量
- 模型暴露包括:1)不提供收容所丁丙诺啡(现状);2)全州收容所提供丁丙诺啡。
研究设计与关键结果
- 研究设计:经济评估研究,使用马萨诸塞州的队列状态转换模拟模型,模拟两个队列(封闭队列和开放队列),数据从2013年开始,数据分析时间为2023年1月至2024年4月。
- 封闭队列分析纳入13 800名PEH(平均[SD]年龄40.4[13.1]岁;男性8749名[63.4%]),收容所丁丙诺啡与个体终生额外65.4人周服用丁丙诺啡相关(与现状相比)。
- 封闭队列中,收容所丁丙诺啡与现状相比具有成本节省效应:从卫生部门角度每人贴现终生费用节省1300美元,每人额外获得0.2个贴现QALY和0.9个额外生命年。
- 人口水平模拟中,10年期间收容所丁丙诺啡策略与现状相比避免254例过量死亡(马萨诸塞州PEH中过量死亡减少9.2%)。
- 与过量相关的未贴现费用减少300万美元,其他医疗保健利用未贴现费用减少6640万美元。
- 收容所阿片类药物治疗产生额外药物和临床费用4470万美元,但节省了6940万美元的过量和其他健康费用。
证据类型、等级与局限
- 证据类型:经济评估研究(队列状态转换模拟模型)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,广泛推广收容所丁丙诺啡可能是应对过量危机的重要工具。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Overdose is the leading cause of death among people experiencing homelessness (PEH), but engagement in medication treatment is low in this population. Shelter-based buprenorphine may be a strategy for increasing initiation and retention on lifesaving medications.
OBJECTIVE: To estimate clinical outcomes and conduct an economic analysis of statewide shelter-based opioid treatment in Massachusetts.
DESIGN, SETTING, AND PARTICIPANTS: This economic evaluation study in Massachusetts used a cohort state-transition simulation model. Two cohorts were modeled starting in 2013, including (1) a closed cohort of a fixed population of PEH with history of high-risk opioid use over their lifetimes and (2) an open cohort in which membership could change over time, allowing assessment of population-level trends over a 10-year period. Data analysis occurred from January 2023 to April 2024.
EXPOSURES: Model exposures included (1) no shelter-based buprenorphine (status quo) and (2) offering buprenorphine in shelters statewide.
MAIN OUTCOMES AND MEASURES: Outcomes included overdose deaths, quality-adjusted life-years (QALYs) gained, and health care and modified societal perspective costs. Sensitivity analyses were conducted on key parameters.
RESULTS: In the closed cohort analysis of 13 800 PEH (mean [SD] age, 40.4 [13.1] years; 8749 male [63.4%]), shelter-based buprenorphine was associated with an additional 65.4 person-weeks taking buprenorphine over an individual's lifetime compared with status quo. Shelter-based buprenorphine was cost saving when compared with the status quo, with a discounted lifetime cost savings from the health sector perspective of $1300 per person, and 0.2 additional discounted QALYs per person and 0.9 additional life-years per person. In the population-level simulation, 254 overdose deaths were averted over the 10-year period with the shelter-based buprenorphine strategy compared with the status quo (a 9.2% reduction of overdose deaths among PEH in Massachusetts). Overdose-related and other health care utilization undiscounted costs decreased by $3.0 million and $66.4 million, respectively. Shelter-based opioid treatment generated $44.7 million in additional medication and clinical costs, but saved $69.4 million in overdose and other health costs.
CONCLUSIONS AND RELEVANCE: In this economic evaluation of clinical and economic outcomes among PEH, shelter-based buprenorphine was associated with fewer overdose deaths and was cost saving. These findings suggest that broad rollout of shelter-based buprenorphine may be an important tool in addressing the overdose crisis.
参考来源
- Chatterjee A, Stewart EA, Assoumou SA, et al. Health and Economic Outcomes of Offering Buprenorphine in Homeless Shelters in Massachusetts. JAMA Netw Open. 2024. PMID: 39412807. doi:10.1001/jamanetworkopen.2024.37233
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。